Lung Cancer
See how Bayer is investigating lung cancer across the pipeline
Follow the connections from areas of research to investigational compounds and the clinical trials evaluating them.
Lung Cancer Overview
Bayer’s lung cancer research is focused on distinct molecular drivers and pathways that may play a role in tumor growth and survival. The current pipeline includes investigational programs targeting HER2, SOS1, KEAP1-NRF2, RAS-PI3Kα, and KRAS-G12D.
Together, these programs represent multiple scientific approaches being investigated across lung cancer, connecting areas of research with compounds in development and their related clinical trials.
4 investigational compounds
4 areas of research
6 clinical trials
Clinical Trials
Tumor Type(s) | Phase | Status | Description | NCT Number |
|---|---|---|---|---|
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRAS-G12C-mutated Solid Tumors | |
Lung Cancer, Solid Tumors, Head and Neck Cancer | I | Now Enrolling | A Phase 1, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of VVD-130037, a Kelch-like ECH Associated Protein 1 (KEAP1) Activator, in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic) | I | Now Enrolling | A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors | |
Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Esophageal, Pancreatic) | I | Now Enrolling | A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS-G12D Mutation | |
Lung Cancer | I/II | Now Enrolling | An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non–small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation | |
Lung Cancer | III | Now Enrolling | A Phase 3 Open-Label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared With Standard of Care as a First-Line Therapy in Patients With Locally Advanced or Metastatic Non–small Cell Lung Cancer (NSCLC) With HER2-Activating Mutations |
Bayer’s Oncology Pipeline Brochure
Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.
The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.
EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; KEAP1, Kelch-like ECH-associated protein 1; KRAS-G12C, Kirsten rat sarcoma viral oncogene homolog with a glycine-to-cysteine substitution at codon 12; KRAS-G12D, Kirsten rat sarcoma viral oncogene homolog with a glycine-to-aspartic acid substitution at codon 12; MAPK, mitogen-activated protein kinase; MTAP, methylthioadenosine phosphorylase; NRF2, nuclear factor erythroid 2–related factor 2; NSCLC, non–small cell lung cancer; PI3Kα, phosphatidylinositol 3-kinase alpha; PRMT5, protein arginine methyltransferase 5; RAS, rat sarcoma; SOS1, son of sevenless homolog 1; TRK, tropomyosin receptor kinase.